The design and synthesis of a library of twenty-six spirotriazoline oxindoles and their in vitro evaluation as potential anticancer agents is reported. The antiproliferative activity of the synthesized compounds was assessed against four different cancer cell lines (HCT-116 p53 ^(+/+), HCT-116 p53 ^(−/−), MCF-7, and MDA-MB-231). Four spirotriazoline oxindoles showed selectivity against the four cancer cell lines tested over the non-cancer derived HEK 293T cell line. To characterize the molecular mechanisms involved in compound antitumoral activity, two spirotriazoline oxindoles were selected for further studies. Both compounds were able to induce apoptosis and cell cycle arrest at G0/G1 phase and upregulated p53 steady-state levels, while decreasing its main inhibitor MDM2, in HCT-116 cells. Importantly, cytotoxic effects induced by spirotriazoline oxindoles occurred in cancer cells without eliciting cell death in non-malignant CCD-18Co human colon fibroblasts. In addition, four spirotriazoline oxindoles showed selectivity against the triple-negative breast cancer cell line MDA-MB-231 with IC₅₀ values of 3.5–6.7 μM. These results highlight the anticancer potential of spirotriazoline oxindoles, especially when dealing with aggressive and challenging triple-negative breast cancer.

报道了二十六个螺三唑啉恶唑的文库的设计和合成，以及作为潜在抗癌药的体外评价。评估了合成化合物对四种不同癌细胞系（HCT-116 p53 ^{（+ / +）}，HCT-116 p53 ^（-/-），MCF-7和MDA-MB-231）。相对于非癌症衍生的HEK 293T细胞系，四个螺三唑啉羟吲哚显示出对四种癌细胞系的选择性。为了表征涉及复合抗肿瘤活性的分子机制，选择了两个螺三唑啉恶吲哚用于进一步研究。在HCT-116细胞中，这两种化合物均能够诱导细胞凋亡和细胞周期停滞在G0 / G1期并上调p53稳态水平，同时降低其主要抑制剂MDM2。重要的是，在非恶性CCD-18Co人结肠成纤维细胞中，螺三唑啉恶唑诱导的细胞毒性作用在癌细胞中发生，而不会引起细胞死亡。此外，四个螺三唑啉恶唑类化合物对具有IC ₅₀的三阴性乳腺癌细胞系MDA-MB-231具有选择性值为3.5–6.7μM。这些结果突出了螺三唑啉恶唑类的抗癌潜力，尤其是在应对侵袭性且极具挑战性的三阴性乳腺癌时。